Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Portfolio Pulse from
Rigel Pharmaceuticals reported its Q4 and full-year 2024 financial results, with total revenue of $57.6 million for Q4 and $179.3 million for the year. The company projects 2025 revenue between $200 and $210 million. R289 received Fast Track and Orphan Drug designations from the FDA.
March 04, 2025 | 9:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Rigel Pharmaceuticals reported strong Q4 and full-year 2024 financial results, with significant revenue from TAVALISSE®, REZLIDHIA®, and GAVRETO®. The company also received FDA designations for R289, potentially boosting future growth.
The strong financial performance in Q4 and full-year 2024, along with FDA designations for R289, suggest positive momentum for Rigel. The projected revenue increase for 2025 further supports a positive short-term outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100